
A groundbreaking advancement in Alzheimer's treatment offers new hope, as the U.S. Food and Drug Administration (FDA) has approved Donanemab, a drug marketed as Kisunla, for individuals in the early stages of the disease.
Kisunla manufactured by Eli Lilly could significantly slow cognitive decline in people with early symptomatic Alzheimer's disease, according to results of the company's clinical trials.